This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schmidt, R. L. Articles by Tang, A. H. Search for Related Content PubMed PubMed Citation Articles by Schmidt, R. L. Articles by Tang, A. H.

Inhibition of RAS-Mediated Transformation and Tumorigenesis by Targeting the Downstream E3 Ubiquitin Ligase Seven in Absentia Homologue

Departments of ¹ Biochemistry and Molecular Biology and ² Surgery, Mayo Clinic Cancer Center, Mayo Clinic College of Medicine, Rochester, Minnesota

Requests for reprints: Amy Tang, Mayo Clinic College of Medicine, 200 First Street Southwest, MS-2-85, Rochester, MN 55905. Phone: 507-538-1878; Fax: 507-284-4957; E-mail: tang.amy{at}mayo.edu.

Constitutively active RAS small GTPases promote the genesis of human cancers. An important goal in cancer biology is to identify means of countervailing activated RAS signaling to reverse malignant transformation. Oncogenic K-RAS mutations are found in virtually all pancreatic adenocarcinomas, making the RAS pathway an ideal target for therapeutic intervention. How to best contravene hyperactivated RAS signaling has remained elusive in human pancreatic cancers. Guided by the Drosophila studies, we reasoned that a downstream mediator of RAS signals might be a suitable anti-RAS target. The E3 ubiquitin ligase seven in absentia (SINA) is an essential downstream component of the Drosophila RAS signal transduction pathway. Thus, we determined the roles of the conserved human homologues of SINA, SIAHs, in mammalian RAS signaling and RAS-mediated tumorigenesis. We report that similar to its Drosophila counterpart, human SIAH is also required for oncogenic RAS signaling in pancreatic cancer. Inhibiting SIAH-dependent proteolysis blocked RAS-mediated focus formation in fibroblasts and abolished the tumor growth of human pancreatic cancer cells in soft agar as well as in athymic nude mice. Given the high level of conservation of RAS and SIAH function, our study provides useful insights into altered proteolysis in the RAS pathway in tumor initiation, progression, and oncogenesis. By targeting SIAH, we have found a novel means to contravene oncogenic RAS signaling and block RAS-mediated transformation/tumorigenesis. Thus, SIAH may offer a novel therapeutic target to halt tumor growth and ameliorate RAS-mediated pancreatic cancer. [Cancer Res 2007;67(24):11798–810]

This article has been cited by other articles:

				C. M. House, A. Moller, and D. D.L. Bowtell Siah Proteins: Novel Drug Targets in the Ras and Hypoxia Pathways Cancer Res., December 1, 2009; 69(23): 8835 - 8838. [Abstract] [Full Text] [PDF]

				K. Nakayama Cellular Signal Transduction of the Hypoxia Response J. Biochem., December 1, 2009; 146(6): 757 - 765. [Abstract] [Full Text] [PDF]

				K. Nakayama, J. Qi, and Z. Ronai The Ubiquitin Ligase Siah2 and the Hypoxia Response Mol. Cancer Res., April 1, 2009; 7(4): 443 - 451. [Abstract] [Full Text] [PDF]

				A. U. Ahmed, R. L. Schmidt, C. H. Park, N. R. Reed, S. E. Hesse, C. F. Thomas, J. R. Molina, C. Deschamps, P. Yang, M. C. Aubry, et al. Effect of Disrupting Seven-in-Absentia Homolog 2 Function on Lung Cancer Cell Growth J Natl Cancer Inst, November 19, 2008; 100(22): 1606 - 1629. [Abstract] [Full Text] [PDF]